When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KTOV - Kitov Pharma launches mid-stage study of NT219 in solid tumors
Kitov Pharma Ltd.
Kitov Pharma (KTOV-6.8%) initiates Phase 1/2 trial of NT219 as monotherapy for advanced solid tumors, as well as in combination with cetuximab, a monoclonal antibody that blocks epithelial growth factor receptor, as a second-line or third-line treatment of recurrent and metastatic squamous cell carcinoma of the Head & Neck Cancer
More news on: Kitov Pharma Ltd, Healthcare stocks news,